Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled trial of SM101 in systemic lupus erythematosus
2010-023396-25Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valziflocept in systemic lupus erythematosus (SLE) (3 arms), sponsored by Baxter International Inc. Primary endpoint: Incidence of adverse events. Started Apr 2011; status: completed.
02
Drugs
valziflocept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-023396-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023396-25.